Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma
Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma
Not yet recruiting · NCT07602101 · Registry updated 2026-05-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, clear cell renal carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Not yet recruiting | Phase 2 | 2026-05-22 | NCT07602101 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chinese PLA General Hospital | 238 |
| Huadong Hospital | 23 |
| RenJi Hospital | 264 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||